Sun Pharma, one of India’s most well-known pharmaceutical companies, has secured a significant legal victory in its ongoing Sun Pharma URSOCOL trademark case against Rambos Lifesciences over trademark infringement of the brand name URSOCOL. The Bombay High Court granted Sun Pharma an interim injunction, restraining Rambos from using the marks URSOCAL and URSOCAL-300, which were found to be deceptively similar to URSOCOL. This order will remain in force until the case is finally decided, and if you want to know more about this case that what has happened till keep reading about this important development in Intellectual Property Rights (IPR).
Why Sun Pharma Took Rambos Lifesciences to Court Over the URSOCOL Trademark
The dispute originated when Rambos Lifesciences launched pharmaceutical products under the names URSOCAL and URSOCAL-300. This move was not acceptable to Sun Pharma, one of India’s leading pharmaceutical companies, which already owned the registered trademark URSOCOL since the early 2000s. Under intellectual property law, such use of a deceptively similar name is considered trademark infringement.
Recognizing the threat to its brand and the potential confusion in the market, Sun Pharma did not hold back and promptly filed a lawsuit against Rambos Lifesciences. In this trademark infringement suit, Sun Pharma raised multiple claims, such as:
- The brand(URSOCOL) has been in use for many years and has strong goodwill in the pharma market.
- The product has major sales, proving its popularity and reputation.
- Rambos Lifesciences launched products named URSOCAL and URSOCAL-300, which Sun claims are deceptively similar to URSOCOL.
- Such similarity could confuse doctors, chemists, and patients, leading to mistakes in prescribing or dispensing medicines.
- Confusion in drug names poses a serious risk to public health.
- Sun Pharma asked the court for an interim injunction to immediately stop Rambos from using those names.
- It also requested a Court Receiver to seize infringing products, packaging, and materials.
- Finally, Sun Pharma sought a permanent injunction and damages to protect its trademark rights and reputation.
Read Also: India Cancels Novartis Vymada Patent, Opens Market to Generics
Why Did the Bombay High Court Grant Interim Relief to Sun Pharma URSOCOL Trademark Case?
The Bombay High Court appointed a Court Receiver to seize infringing goods from Rambos Lifesciences, and the Receiver later carried out the order and filed a report on the seizures. Following this, the Court granted Sun Pharma an interim injunction, stopping Rambos and its associates from using the names URSOCAL and URSOCAL-300. The judge stressed that confusion in pharmaceutical products could have serious consequences, making strong protection necessary. The injunction will remain in place until the case is fully decided, giving Sun Pharma temporary protection of its trademark rights. The matter was then adjourned for further hearing, as Rambos Lifesciences had not yet been fully served.
What’s Next in the Sun Pharma vs Rambos Lifesciences URSOCOL Trademark Case?
The Sun Pharma vs Rambos Lifesciences trademark dispute will continue in the Bombay High Court, with the next hearing set after the case was adjourned due to incomplete service on Rambos. The interim injunction remains in place, preventing Rambos from using URSOCAL or URSOCAL-300 until the case is finally decided. In the coming hearings, Rambos is expected to present its defense, while the court will examine the similarity of the marks, the risk of confusion, and the potential impact on public health before reaching a final judgment.
Conclusion
The Sun Pharma vs Rambos Lifesciences case highlights the critical importance of protecting trademarks in the pharmaceutical industry, where even slight confusion can put patient safety at risk. With the interim injunction already in place, the outcome of this legal battle will not only decide the future of the URSOCOL brand but also reinforce the role of Intellectual Property Rights (IPR) in safeguarding innovation and trust in healthcare.
Read Also: Samsung Settles $279M Wireless Patent Lawsuit in U.S. After Jury Verdict